Recent clinical trials showcased at IASLC 2025 reveal breakthroughs in treating EGFR-mutated non-small cell lung cancer. The FLAURA2 study demonstrated that combining osimertinib and chemotherapy extends overall survival. Additional studies report significant progression-free survival improvements with ivonescimab and aumolertinib paired with chemotherapy. A novel bispecific ADC, iza-bren, achieved a 100% objective response rate when combined with osimertinib, marking a new milestone in targeted lung cancer therapies.